API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.
Lead Product(s): Aspirin,Ramipril,Simvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Polypill
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CNIC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2022
Details:
Ramipril will be assessed for its potential to decrease the severity of Covid-19, lower intensive care unit admission rates, mechanical ventilators use, and all-cause mortality.
Lead Product(s): Ramipril
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2020